A study analysing safety and efficacy of icotinib combined with concurrent chemoradiotherapy in locally advanced cervical cancer
Latest Information Update: 17 Jun 2021
Price :
$35 *
At a glance
- Drugs Icotinib (Primary) ; Antineoplastics
- Indications Cervical cancer
- Focus Adverse reactions; Therapeutic Use
- 17 Jun 2021 New trial record
- 01 May 2021 Results published in the Neoplasma